Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Determination of benchmark concentrations and their statistical uncertainty for cytotoxicity test data and functional in vitro assays

  • Krebs, Alice
  • Nyffeler, Johanna
  • Karreman, Christiaan
  • Schmidt, Béla Z.
  • Kappenberg, Franziska
  • Mellert, Jan
  • Pallocca, Giorgia
  • Pastor Maeso, Manuel
  • Rahnenführer, Jörg
  • Leist, Marcel
Many toxicological test methods, including assays of cell viability and function, require an evaluation of concentration-response data. This often involves curve fitting, and the resulting mathematical functions are then used to determine the concentration at which a certain deviation from the control value occurs (e.g. a decrease of cell viability by 15%). Such a threshold is called the benchmark response (BMR). For a toxicological test, it is often of interest to determine the concentration of test compound at which a pre-defined BMR of e.g. 10, 25 or 50% is reached. The concentration at which the modelled curve crosses the BMR is called the benchmark concentration (BMC). We present a user-friendly, web-based tool (BMCeasy), designed for operators without programming skills and profound statistical background, to determine BMCs and their confidence intervals. BMCeasy allows simultaneous analysis of viability plus a functional test endpoint, and it yields absolute BMCs with confidence intervals for any BMR. Besides an explanation of the algorithm underlying BMCeasy, this article also gives multiple examples of data outputs. BMCeasy was used within the EU-ToxRisk project for preparing data packages that were submitted to regulatory authorities, demonstrating the real-life applicability of the tool., This work was supported by the BMBF, EFSA, the DK-EPA, and the DFG (Konstanz Research School of Chemical Biology; KoRS-CB). It has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs). We are grateful to collaborators R. von Hellfeld and T. Braunbeck (University of Heidelberg), and H. Vrieling and J. Boei (Leiden University Medical Center) of the EU-ToxRisk con-sortium for providing the experimental data. We are indebted to S. Förster for triggering this work and to other colleagues for in-sightful discussions.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

In vitro teratogenicity testing using a 3D, embryo-like gastruloid system

  • Mantziou, Veronika
  • Baillie-Benson, Peter
  • Jaklin, Manuela
  • Kustermann, Stefan
  • Martinez Arias, Alfonso
  • Moris, Naomi
Pharmaceuticals intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles ('replace, reduce and refine') by streamlining the selection of promising compounds submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D 'gastruloid' model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA, and SOX17, suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system., This work was supported by grants from Medical Research Council (MRC) (MR/R017190/1 and MR/V005367/1) to A.M.A. and N.M., a Leverhulme Trust grant (RPG-2018-356) to AMA, as well as a Gates Cambridge Scholarship awarded to V.M.. The mouse part was supported by an ERC Advanced investigator grant (AdG 834580) to A.M.A. supporting P.B.B. Data derived from human iPSC in vitro model based compound assessment has been supported by the BMBF, EFSA, and the DK-EPA (MST-667-00205) and received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In vitro teratogenicity testing using a 3D, embryo-like gastruloid system

  • Mantziou, Veronika
  • Baillie-Benson, Peter
  • Jaklin, Manuela
  • Kustermann, Stefan
  • Martinez Arias, Alfonso
  • Moris, Naomi
Pharmaceuticals intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles ('replace, reduce and refine') by streamlining the selection of promising compounds submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D 'gastruloid' model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA, and SOX17, suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system., This work was supported by grants from Medical Research Council (MRC) (MR/R017190/1 and MR/V005367/1) to A.M.A. and N.M., a Leverhulme Trust grant (RPG-2018-356) to AMA, as well as a Gates Cambridge Scholarship awarded to V.M.. The mouse part was supported by an ERC Advanced investigator grant (AdG 834580) to A.M.A. supporting P.B.B. Data derived from human iPSC in vitro model based compound assessment has been supported by the BMBF, EFSA, and the DK-EPA (MST-667-00205) and received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Determination of benchmark concentrations and their statistical uncertainty for cytotoxicity test data and functional in vitro assays

  • Krebs, Alice
  • Nyffeler, Johanna
  • Karreman, Christiaan
  • Schmidt, Béla Z.
  • Kappenberg, Franziska
  • Mellert, Jan
  • Pallocca, Giorgia
  • Pastor Maeso, Manuel
  • Rahnenführer, Jörg
  • Leist, Marcel
Many toxicological test methods, including assays of cell viability and function, require an evaluation of concentration-response data. This often involves curve fitting, and the resulting mathematical functions are then used to determine the concentration at which a certain deviation from the control value occurs (e.g. a decrease of cell viability by 15%). Such a threshold is called the benchmark response (BMR). For a toxicological test, it is often of interest to determine the concentration of test compound at which a pre-defined BMR of e.g. 10, 25 or 50% is reached. The concentration at which the modelled curve crosses the BMR is called the benchmark concentration (BMC). We present a user-friendly, web-based tool (BMCeasy), designed for operators without programming skills and profound statistical background, to determine BMCs and their confidence intervals. BMCeasy allows simultaneous analysis of viability plus a functional test endpoint, and it yields absolute BMCs with confidence intervals for any BMR. Besides an explanation of the algorithm underlying BMCeasy, this article also gives multiple examples of data outputs. BMCeasy was used within the EU-ToxRisk project for preparing data packages that were submitted to regulatory authorities, demonstrating the real-life applicability of the tool., This work was supported by the BMBF, EFSA, the DK-EPA, and the DFG (Konstanz Research School of Chemical Biology; KoRS-CB). It has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs). We are grateful to collaborators R. von Hellfeld and T. Braunbeck (University of Heidelberg), and H. Vrieling and J. Boei (Leiden University Medical Center) of the EU-ToxRisk con-sortium for providing the experimental data. We are indebted to S. Förster for triggering this work and to other colleagues for in-sightful discussions.